Literature DB >> 12488458

Characterization of the transforming growth factor-beta 1-induced apoptotic transcriptome in FaO hepatoma cells.

Beth Coyle1, Caroline Freathy, Timothy W Gant, Ruth A Roberts, Kelvin Cain.   

Abstract

We have previously shown that transforming growth factor-beta(1) (TGF-beta(1))-induced apoptosis in FaO hepatoma cells is mediated by cytochrome c release, apoptosome formation, and caspase activation. Although TGF-beta(1) acts via the SMAD signaling pathway to initiate de novo gene transcription, little is known about the downstream gene targets that are involved in the regulation of apoptosis. Therefore, in this study, we used in-house microarrays (approximately 5500 genes) to identify pathway-specific gene clustering in TGF-beta(1)-treated cells. A total of 142 genes showed time-dependent changes in expression during TGF-beta(1)-induced apoptosis. The polycaspase inhibitor benzyloxycarbonyl-VAD-fluoromethyl ketone, which, on its own, had no effect on gene transcription, blocked TGF-beta(1)-induced cell death and significantly altered the expression of 261 genes, including 185 down-regulated genes. Cluster analysis identified up-regulation of early response genes (0-4 h) encoding for the extracellular matrix and cytoskeleton, including the pro-apoptotic CTGF gene, and delayed response genes (8-16 h), including pro-apoptotic genes. A second delayed response cluster (44 genes) was also observed when TGF-beta(1)-induced caspase activation was blocked by benzyloxycarbonyl-VAD-fluoromethyl ketone. This cluster included genes encoding stress-related proteins (e.g. Jun, ATF3, TAB1, and TANK), suggesting that their up-regulation may be in response to secondary necrosis. Finally, we identified an early response set of nine down-regulated genes that are involved in antioxidant defense. We propose that the regulation of these genes by TGF-beta(1) could provide a molecular mechanism for the observed elevation in reactive oxygen species after TGF-beta(1) treatment and may represent the primary mechanism through which TGF-beta(1) initiates apoptosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12488458     DOI: 10.1074/jbc.M211300200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  TSC-22 promotes transforming growth factor β-mediated cardiac myofibroblast differentiation by antagonizing Smad7 activity.

Authors:  Xiaohua Yan; Junyu Zhang; Lin Pan; Peng Wang; Hua Xue; Long Zhang; Xia Gao; Xingang Zhao; Yuanheng Ning; Ye-Guang Chen
Journal:  Mol Cell Biol       Date:  2011-07-26       Impact factor: 4.272

2.  TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition.

Authors:  Ulrich Valcourt; Marcin Kowanetz; Hideki Niimi; Carl-Henrik Heldin; Aristidis Moustakas
Journal:  Mol Biol Cell       Date:  2005-02-02       Impact factor: 4.138

3.  Epithelial cell TGFβ signaling induces acute tubular injury and interstitial inflammation.

Authors:  Madeleine E Gentle; Shaolin Shi; Ilse Daehn; Taoran Zhang; Haiying Qi; Liping Yu; Vivette D D'Agati; Detlef O Schlondorff; Erwin P Bottinger
Journal:  J Am Soc Nephrol       Date:  2013-03-28       Impact factor: 10.121

4.  Transforming growth factor-beta1 expression is up-regulated in maturation-stage enamel organ and may induce ameloblast apoptosis.

Authors:  Masahiro Tsuchiya; Ramaswamy Sharma; Coralee E Tye; Toshihiro Sugiyama; John D Bartlett
Journal:  Eur J Oral Sci       Date:  2009-04       Impact factor: 2.612

5.  Adenovirus E1A and E1B-19K proteins protect human hepatoma cells from transforming growth factor beta1-induced apoptosis.

Authors:  Vera L Tarakanova; William S M Wold
Journal:  Virus Res       Date:  2009-10-23       Impact factor: 3.303

6.  Anti-tumor effects of Abnormal Savda Munziq on the transplanted cervical cancer (U27) mouse model.

Authors:  Zuhragul Omarniyaz; Yang Yu; Tao Yang; Lianlian Shan; Weiwei Miao; Renaguli Reyimu; Halmurat Upur; Ainiwaer Aikemu
Journal:  BMC Complement Altern Med       Date:  2016-11-24       Impact factor: 3.659

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.